Thyroid Disorders

Highlights Autoantibodies refine autoimmune thyroid disorder diagnosis and risk. Thyroid-stimulating hormone receptor antibody predicts relapse, severity and foetal impact. Thyroid peroxidase antibody and thyroglobulin antibody linked to fertility outcomes. Novel antibodies expand thyroid autoimmunity scope. The interplay between immunology and ...

There is no doubt that artificial intelligence was one of the fastest-moving technologies of 2025. Advances in predictive analytics, pattern recognition across large datasets, and the integration of genomic, phenotypic and real-world data are already beginning to reshape how clinicians diagnose disease, stratify risk and personalise care. We asked some of the experts that have collaborated with touchENDOCRINOLOGY what excites them most about AI and how they see it influencing clinical practice.

In this roundup, members of the touchNDOCRINOLOGY Expert Faculty share their perspectives on the advances that shaped research and practice over the past year, highlighting a discipline in transition and looking ahead to the opportunities of 2026.

Welcome to the latest edition of touchREVIEWS in Endocrinology, which features a diverse selection of editorials, reviews and original research articles that highlight both the progress and the ongoing challenges in translating pathophysiological insight into patient-centred care. We begin with ...

As touchENDOCRINOLOGY approaches 22 years of providing education for busy endocrinologists, we are looking to the future—and it certainly looks bright! This year, we are celebrating our inaugural touchENDOCRINOLOGY Future Leaders to recognize the outstanding talent that has entered our ...

Thyroid eye disease (TED), also known as Graves’ orbitopathy, is a complex autoimmune disorder driven by an interplay of immune cells, orbital fibroblasts and tissue remodelling factors that lead to inflammation, oedema and, ultimately, potential vision loss.1 While the disease ...

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.

Eneboparatide is an investigational parathyroid hormone receptor 1 (PTH1R) agonist, designed to bind with high affinity to a specific conformation of PTH1R, which is expressed in the kidneys and bone. The goal of treatment is to restore function by producing sustained and stable levels of calcium in the blood and by restoring calcium reabsorption by the kidney.2,3 Eneboparatide has been developed to have a short half-life in order to preserve bone health.